INO-1001
- Generic Name
- INO-1001
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N3O7S2
- CAS Number
- 501364-91-6
- Unique Ingredient Identifier
- 55E08EN074
- Indication
Investigated for use/treatment in brain cancer, cardiovascular disorders, and myocardial infarction.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
- First Posted Date
- 2006-01-06
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00272415
A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2006-11-29
- Lead Sponsor
- Inotek Pharmaceuticals Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00271765
- Locations
- 🇺🇸
Porter Hospital, Valparaiso, Indiana, United States
🇮🇱Assaf Harofe Medical Centre, Zerifin, Israel
🇺🇸Toledo Hospital, Toledo, Ohio, United States
A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-12-30
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Inotek Pharmaceuticals Corporation
- Target Recruit Count
- 162
- Registration Number
- NCT00271167
- Locations
- 🇺🇸
University of Oklahoma, Oklahoma, Oklahoma, United States
🇦🇺Royal Perth Hospital, Perth, Western Australia, Australia
🇦🇺St. Vincent's Hospital, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath